Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

A phase I trial of ABT-888 (veliparib), a poly(ADP-ribose) polymerase (PARP inhibitor), in combination with topotecan, a topoisomerase I–targeted agent, was performed to determine maximum tolerated dose (MTD), safety, pharmacokinetics, and pharmacodynamics of the combination in patients with refract...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kummar, Shivaani, Chen, Alice, Ji, Jiuping, Zhang, Yiping, Reid, Joel M., Ames, Matthew, Jia, Lee, Weil, Marcie, Speranza, Giovanna, Murgo, Anthony J., Kinders, Robert, Wang, Lihua, Parchment, Ralph E., Carter, John, Stotler, Howard, Rubinstein, Larry, Hollingshead, Melinda, Melillo, Giovanni, Pommier, Yves, Bonner, William, Tomaszewski, Joseph E., Doroshow, James H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3166628/
https://ncbi.nlm.nih.gov/pubmed/21795476
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-1227
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados